Publications of Edgar Meinl
All genres
Journal Article (58)
2012
Journal Article
209 (3), pp. 521 - 535 (2012)
Stimulation of the neurotrophin receptor TrkB on astrocytes drives nitric oxide production and neurodegeneration. Journal of Experimental Medicine
Journal Article
25 (3), pp. 231 - 238 (2012)
Identifying autoantigens in demyelinating diseases: Valuable clues to diagnosis and treatment? Current Opinion in Neurology
Journal Article
22 (5), pp. 607 - 618 (2012)
Prospects of transcript profiling for mRNAs and microRNAs using formalin-fixed and paraffin-embedded dissected autoptic multiple sclerosis lesions. Brain Pathology
Journal Article
22, pp. 607 - 618 (2012)
Prospects of transcript profiling for mRNAs and microRNAs using formalin fixed and paraffin embedded dissected autoptic multiple sclerosis lesions. Brain Pathology
Journal Article
135, pp. 1819 - 1833 (2012)
Functional identification of pathogenic autoantibody responses in patients with multiple sclerosis. Brain
Journal Article
8 (11), pp. 613 - 623 (2012)
B cells and antibodies in multiple sclerosis pathogenesis and therapy. Nature Reviews Neurology
Journal Article
319 (1-2), pp. 2 - 7 (2012)
Viability of autoantibody-targets: How to tackle pathogenetic heterogeneity as an obstacle for treatment of multiple sclerosis. JOURNAL OF THE NEUROLOGICAL SCIENCES
Journal Article
5 (3), pp. 147 - 159 (2012)
Glycoproteins as targets of autoantibodies in CNS inflammation: MOG and more. Therapeutic Advances in Neurological Disorders
Journal Article
79 (22), pp. 2162 - 2163 (2012)
MicroRNAs in the CSF Macro-advance in MS? Neurology
Journal Article
79 (23), pp. 2241 - 2248 (2012)
Neurofascin as a target for autoantibodies in peripheral neuropathies. Neurology 2011
Journal Article
85 (19), pp. 9680 - 9685 (2011)
Expression of herpes simplex virus 1-encoded microRNAs in human trigeminal ganglia and their relation to local T-cell infiltrates. Journal of Virology
Journal Article
7 (1), pp. 56 - 59 (2011)
The emerging role of microRNAs in multiple sclerosis. Nature Reviews Neurology
Journal Article
311 (Suppl. 1), pp. S12 - S15 (2011)
Untapped targets in multiple sclerosis. Journal of the Neurological Sciences
Journal Article
306 (1-2), pp. 180 - 182 (2011)
Humoral autoimmunity in multiple sclerosis. Journal of the Neurological Sciences
Journal Article
76 (15), pp. 1310 - 1315 (2011)
Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab. Neurology
Journal Article
77 (6), pp. 580 - 588 (2011)
Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis. Neurology 2010
Journal Article
88 (8), pp. 753 - 761 (2010)
Axo-glial antigens as targets in multiple sclerosis: Implications for axonal and grey matter injury. Journal of Molecular Medicine
Journal Article
1 (2), pp. 47 - 60 (2010)
Identifying targets for autoantibodies in CNS inflammation: Strategies and achievements. Clinical and Experimental Neuroimmunology
Journal Article
20 (5), pp. 966 - 975 (2010)
Extracellular matrix in multiple sclerosis lesions: Fibrillar collagens, biglycan and decorin are upregulated and associated with infiltrating immune cells. Brain Pathology 2009
Journal Article
106 (20), pp. 8302 - 8307 (2009)
Contactin-2/TAG-1-directed autoimmunity is identified in multiple sclerosis patients and mediates gray matter pathology in animals. Proceedings of the National Academy of Sciences of the United States of America
Journal Article
31 (4), pp. 467 - 477 (2009)
Novel approaches for identifying target antigens of autoreactive human B and T cells. Seminars in Immunopathology
Journal Article
132, pp. 3342 - 3352 (2009)
MicroRNA profiling of multiple sclerosis lesions identifies modulators of the regulatory protein CD47. Brain
Journal Article
158 (3), pp. 1122 - 1132 (2009)
Neuro-immune crosstalk in CNS. Neuroscience 2008
Journal Article
197 (2), pp. 128 - 139 (2008)
BDNF and its receptors in human myasthenic thymus: Implications for cell fate in thymic pathology. Journal of Neuroimmunology
Journal Article
35 (7), pp. 345 - 355 (2008)
Autoantigen- und erregerspezifische T- und B-Zellreaktionen bei multipler Sklerose: „Eine unendliche Geschichte”? Aktuelle Neurologie
Journal Article
274 (1-2), pp. 5 - 8 (2008)
B- and T-cell responses in multiple sclerosis: Novel approaches offer new insights. Journal of Neurological Sciences
Journal Article
131, pp. 1455 - 1463 (2008)
Interferon-β increases BAFF levels in multiple sclerosis: Implications for B cell autoimmunity. Brain
Journal Article
71 (17), pp. 1350 - 1354 (2008)
Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis. Neurology
Journal Article
16, pp. 367 - 373 (2008)
Myofibrillar myopathy with arrhythmogenic right ventricular cardiomyopathy 7: Corroboration and narrowing of the critical region on 10q22.3. European Journal of Human Genetics
Journal Article
274 (1-2), pp. 42 - 44 (2008)
Compartmentalization of inflammation in the CNS: A major mechanism driving progressive multiple sclerosis. Journal of Neurological Sciences 2007
Journal Article
17 (4), pp. 389 - 398 (2007)
Presence of HSV-1 immediate early genes and clonally expanded T-cells with a memory effector phenotype in human trigeminal ganglia. Brain Pathology
Journal Article
28 (3), pp. 138 - 145 (2007)
Astrocytes are active players in cerebral innate immunity. Trends in Immunology
Journal Article
68 (12), pp. 958 - 959 (2007)
Multiple sclerosis: Relating MxA transcription to anti-interferon-β-neutralizing antibodies. Neurology
Journal Article
68 (3), pp. 58 - 63 (2007)
Dual role of inflammation in CNS disease. Neurology
Journal Article
130, pp. 2789 - 2799 (2007)
Multiple sclerosis: T-cell receptor expression in distinct brain regions. Brain
Journal Article
190 (1-2), pp. 72 - 79 (2007)
CCL19 is constitutively expressed in the CNS, up-regulated in neuroinflammation, active and also inactive multiple sclerosis lesions. Journal of Neuroimmunology
Journal Article
204 (10), pp. 2363 - 2372 (2007)
Neurofascin as a novel target for autoantibody-mediated axonal injury. Journal of Experimental Medicine 2006
Journal Article
129, pp. 200 - 211 (2006)
Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment. Brain
Journal Article
60 (4), p. 487 - 487 (2006)
B lineage cells in inflammatory central nervous system - Reply. Annals of Neurology
Journal Article
59 (6), pp. 880 - 892 (2006)
B lineage cells in the inflammatory central nervous system environment: Migration, maintenance, local antibody production, and therapeutic modulation. Annals of Neurology 2005
Journal Article
252 (8), pp. 968 - 971 (2005)
Intrathecal antibody (IgG) production against human herpesvirus type 6 occurs in about 20% of multiple sclerosis patients and might be linked to a polyspecific B-cell response. Journal of Neurology
Journal Article
159 (1-2), pp. 12 - 19 (2005)
Preferential expression and function of Toll-like receptor 3 in human astrocytes. Journal of Neuroimmunology
Journal Article
4 (9), pp. 567 - 575 (2005)
Glatiramer acetate in multiple sclerosis: Update on potential mechanisms of action. Lancet Neurology
Journal Article
25 (4), pp. 298 - 302 (2005)
BAFF is elevated in serum of patients with Wegener's granulomatosis. Journal of Autoimmunity
Journal Article
201 (2), pp. 195 - 200 (2005)
BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. Journal of Experimental Medicine
Journal Article
58 (1), pp. 110 - 111 (2005)
Differential expression of CD150 (SLAM) on monocytes and macrophages in chronic inflammatory contexts: Abundant in Crohn's disease, but not in multiple sclerosis. Journal of Clinical Pathology
Journal Article
175 (4), pp. 2301 - 2308 (2005)
Expression and function of glial cell line-derived neurotrophic factor (GDNF) family ligands and their receptors on human immune cells. Journal of Immunology 2004
Journal Article
16 (6), pp. 799 - 809 (2004)
Distinct responses of monocytes to Toll-like receptor ligands and inflammatory cytokines. International Immunology
Journal Article
2, p. 517 - 517 (2004)
Biomarker in der Therapie der Multiplen Sklerose: Läßt sich der Erfolg bald vorhersagen? MMW-Fortschr. Med. Sonderheft
Journal Article
127, pp. 1370 - 1378 (2004)
Multiple sclerosis: Glatiramer acetate inhibits monocyte reactivity in vitro and in vivo. Brain